Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
June 14, 2022 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
April 06, 2022 12:14 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric...
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
January 24, 2022 15:52 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
RIVANNA® Expands World-Class Engineering Team to Advance Development of the Accuro® Product Platform
January 18, 2022 06:00 ET
|
Rivanna Medical
CHARLOTTESVILLE, Va., Jan. 18, 2022 (GLOBE NEWSWIRE) -- RIVANNA®, developers of world-first, imaging-based medical solutions, today announced the appointment of Paul Sheeran, Ph.D., as senior...
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
November 17, 2021 06:42 ET
|
Vir Biotechnology, Inc.
– US government contracts for approximately $1 billion1 (USD) now in place to purchase sotrovimab, further expanding access nationwide – – This brings the total number of doses secured through...
RIVANNA Purchases New Facility Signaling Rapid Growth
November 09, 2021 06:00 ET
|
Rivanna Medical
CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- RIVANNA®, developers of world-first, imaging-based medical solutions, today announced the purchase of a 10,000 square-foot facility in...
RIVANNA announces award from U.S. government to develop Accuro Platform for rapid triage of blast-related injuries
October 26, 2021 09:00 ET
|
RIVANNA
CHARLOTTESVILLE, Va., Oct. 26, 2021 (GLOBE NEWSWIRE) -- RIVANNA®, developers of imaging-based medical solutions, announced that they have received a contract from the Biomedical Advanced Research...
Sabin Vaccine Institute Receives Additional $34.5 Million from BARDA for Further Development of Ebola Sudan and Marburg Vaccines
October 21, 2021 09:47 ET
|
The Sabin Vaccine Institute
Washington DC, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the...
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021
September 29, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...